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Abstract. The molecular mechanisms by which glioblas-
toma multiforme (GBM) refracts and becomes resistant to 
radiotherapy treatment remains largely unknown. This radio-
resistance is partly due to the presence of hypoxic regions, 
which are frequently found in GBM tumors. We investigated 
the radiosensitizing effects of MEK/ERK inhibition on GBM 
cell lines under hypoxic conditions. Four human GBM cell 
lines, T98G, U87MG, U138MG and U251MG were treated 
with the MEK/ERK inhibitor U0126, the HIF-1α inhibitor 
FM19G11 or γ-irradiation either alone or in combination under 
hypoxic conditions. Immunoblot analysis of specific proteins 
was performed in order to define their anti-oncogenic or 
radiosensitizing roles in the different experimental conditions. 
MEK/ERK inhibition by U0126 reverted the transformed 
phenotype and significantly enhanced the radiosensitivity of 
T98G, U87MG, U138MG cells but not of the U251MG cell 
line under hypoxic conditions. U0126 and ERK silencing by 
siRNA reduced the levels of DNA protein kinase catalytic 
subunit (DNA-PKcs), Ku70 and K80 proteins and clearly 
reduced HIF-1α activity and protein expression. Furthermore, 
DNA-PKcs siRNA-mediated silencing counteracted HIF-1α 
activity and downregulated protein expression suggesting that 
ERKs, DNA-PKcs and HIF-1α cooperate in radioprotection of 
GBM cells. Of note, HIF-1α inhibition under hypoxic condi-
tions drastically radiosensitized all cell lines used. MEK/ERK 
signal transduction pathway, through the sustained expression 
of DNA-PKcs, positively regulates HIF-1α protein expression 
and activity, preserving GBM radioresistance in hypoxic 
condition.
Introduction
Glioblastoma (GBM) is the most common and aggressive type 
of primary brain cancer in adults (1). Despite multimodality 
treatment consisting of maximally safe resection, adjuvant 
chemoradiation with temozolomide, median survival remains 
dismal at 12-15 months (2), where less than 2% of patients 
survive 3 years post-diagnosis (3). Infiltrating cancer cells 
in the surrounding brain that prevent complete resection and 
their intrinsic resistance to chemoradiation treatment cause 
the poor prognosis of the GBM patient (4,5). GBM that arise 
de novo usually occurs as the result of progression from lower 
grade astrocytomas. Several histological changes occur during 
transition to GBM and these reflect a profound alteration in 
the tumor vascular biology. Particularly, the main change is 
represented by the appearance of hypoxic areas bounded by 
regions with a high rate of cell proliferation (6,7). In GBM 
hypoxia and its microenvironment are predominant features 
associated with the tumor growth, progression and resistance 
to chemo- and radiation therapies (8-10). Furthermore, it has 
been shown that hypoxia favors the maintenance of GBM 
stem cell population that is intrinsically resistant to standard 
therapies (11,12). Thus, targeting the molecular mechanism 
regulated by hypoxia could represent a valid alternative 
strategy in order to chemoradio-sensitize GBM cells (13). 
One of the main early cellular events evoked upon exposure 
to hypoxia is activation of HIF-1 transcription factor that, 
through the binding of hypoxia-responsive elements (HREs), 
induces the expression of several target genes involved in 
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tumor angiogenesis, invasion, cell survival and glucose 
metabolism (14). Very little is known about the molecular 
mechanisms implicated in hypoxia-induced resistance to 
therapies, although the central role of HIF-1α in promoting 
the cancer cells resistance to therapies has been reported. 
Eukaryotic cells respond to hypoxia through the modulation 
of several downstream effector pathways, including intracel-
lular signal transduction cascades, which in turn interfere 
with gene expression regulation. In particular, members of 
the family of mitogen activated protein (MAP) kinases were 
shown to be involved in the transduction of the hypoxic signals 
(15-17). Even though the mitogenic Ras/Raf/MEK/ERK 
cascade signalling pathway, which responds to growth 
factors and factors inducing cellular differentiation, such 
as epidermal growth factor (EGF) and platelet derived 
growth factor (PDGF), has been intensively studied (18), 
little is known about its relationship to hypoxia (19). It has 
been shown that ERKs, activated during hypoxia, positively 
regulate HIF-1α gene expression (20), phosphorylate HIF-1α 
protein regulating its activity (21) and are needed for its 
activity as a transcription factor (22). Resistance to chemo- 
and radiotherapy may be caused primarily by DNA repair 
mechanisms (23). The main deleterious damage induced 
by chemo- and radiotherapy is DNA-double-strand breaks 
(Dsbs) and DNA repair remains one of the main responses 
through which cancer cells guarantee their own survival thus 
contributing to tumor chemo- and radioresistance. The major 
mechanism underlying the repair of DNA-Dsbs in mamma-
lian cells requires the DNA-PKcs, a serine-threonine protein 
kinase that forms a complex of 450,000 kDa catalytic subunit 
(DNA-PKcs), in a heterodimeric complex composed of the 
proteins Ku70 (70,000 Da) and Ku80 (86,000 Da). Ku binds 
to both ends of a double-strand break and recruits DNA-PKcs 
to the DNA end (24,25). Functional interplay has been shown 
between HIF-1α and DNA-PKcs, which could contribute 
to radio resistance and chemoresistance in hypoxic tumor 
cells (26). GBM is characterized by several aberrantly acti-
vated signalling pathways such as EGF, vascular endothelial 
growth factor receptor (VEGF) and PDGF pathways (27,28). 
All these pathways converge on the RAS-MEKs-ERKs signal 
transduction activation that plays a key role in the regulation 
of tumor progression and treatments response (29). Herein, 
the role of RAS-MEKs-ERKs signal transduction pathway 
in controlling GBM transformed phenotype and response 
to radiotherapy treatment was investigated under hypoxic 
condition. Our results showed that RAS/MAPK pathway, 
through the regulation of DNA-PKcs/HIF-1α interplay, 
governs the GBM transformed phenotype and regulates 
the hypoxia-mediated increase of GBM radioresistance. 
Particularly we showed for the first time that DNA-PKcs is 
an upstream regulator of HIF-1α protein expression, which is 
the determinant in sustaining GBM refractoriness to radiation 
therapy.
Materials and methods
Cell cultures in conventional and hypoxic conditions: treat-
ments and radiation exposure. The human glioblastoma 
T98G and U138MG cell lines were obtained from American 
Type Culture Collection (Manassas, VA, USA). The human 
glioblastoma U87MG cell lines were from Life Technologies 
(Frederick, MD, USA). The human glioblastoma U251MG 
cell lines were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). The T98G U138MG and U251MG cell lines were 
cultured in Eagle's minimum essential medium containing 
fetal bovine serum to a final concentration of 10%. The 
U87MG cell lines were cultured in RPMI-1640 medium 
containing fetal bovine serum to a final concentration of 
10%. The cell lines are tested in our laboratory every year for 
the expression of specific markers by western blot analysis 
and were last tested in 2012. For hypoxia experiments, 
cultures were maintained at 37˚C in a humidified incubator 
in an atmosphere of 20% O2, 5% CO2 and 75% N2. The Xvivo 
Closed Incubation System (Xvivo system 300 C, BioSpherix, 
New York, NY, USA) was used in this study in order to 
accurately maintain different oxygen tensions in different 
chambers. After 24 h of cultivation in conventional cell 
culture (allowing cells to attach onto the flasks), the cells were 
transferred into different chambers with 0.1% O2, 5% CO2 and 
94.9% N2 for variable periods of time before being harvested 
for additional analysis. Treatment with 10 µmol/l MEK/
ERK inhibitor U0126 (1,4-diamino-2,3-dicyano-1,4-bis[2-
aminophenylthio]butadiene; Promega, Madison, WI, USA) or 
300 mM HIF-1α inhibitor FM19G11 [2-oxo-2-(p-tolyl)ethyl] 
3-[(2,4-dinitrobenzoyl)amino]benzoate, 3-[(2,4-dinitroben-
zoyl)amino]-benzoic acid 2-(4-methylphenyl)-2-oxoethyl 
ester were done for the times shown in the figures and started 
before radiation, lasting for 24 h. Radiation was delivered at 
room temperature using an x-6 MV photon linear accelerator 
as already described (30). The total single dose of 400 cGy 
was delivered with a dose rate of 2 Gy/min using a source-to-
surface distance (SSD) of 100 cm. Doses of 200 kV X-rays 
(Yxlon Y.TU 320; Yxlon, Copenhagen, Denmark) filtered 
with 0.5 mm Cu. The absorbed dose was measured using a 
Duplex dosimeter (PTW, Freiburg, Germany). The dose-rate 
was approximately 1.3 Gy/min and applied doses ranged 
from 0 to 600 cGy.
Immunoblot analysis. Immunoblot analysis was performed as 
described (31). Briefly, cells were lysed in 2% SDS containing 
phosphatase and protease inhibitors sonicated for 30 sec. 
Proteins of whole cell lysates were assessed using the method 
of Lowry et al (32), and equal amounts were separated on 
SDS-PAGE. The proteins were transferred to a nitrocellulose 
membrane (Schleicher & Schuell, BioScience GmbH, Dassel, 
Germany) by electroblotting. Immunoblot analyses were 
performed with the following antibodies: anti-c-Myc (9E10), 
anti-N-Myc (C-19), anti-phospho ERK1/2 (E-4), anti-ERK2 
(C-14 positive also for ERK1), anti-cyclin-D1 (M-20), 
anti-HIF-1α (28b), anti-DNA-PKcs (28b), α-tubulin (B-7) 
all from Santa Cruz Biotechnology (Santa Cruz, CA, USA) 
and anti-Ku70/Ku80 (ab53126) from Abcam (Cambridge, 
UK). Peroxidase-conjugate anti-mouse or anti-rabbit IgG 
(Amersham-Pharmacia Biotech, Amersham, UK or Santa 
Cruz) were used for enhanced chemiluminescence (ECL) 
detection.
Cell proliferation, soft agar assays and FACS analysis. Cells 
from adherent and suspension culture were counted using 
hemocytometer, and tested for exclusion of trypan blue. Data 
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are expressed as mean ± SE of experiments performed in trip-
licate. Suspension culture proliferation assay was performed 
by using polyHema assay as already described (36). Briefly, 
polyHEMA-coated 96-well plates were used. A total of 50 µl 
of polyHEMA solution (5 mg/ml in 95% ethanol) was overlaid 
into wells and dried for 2 days with lids in place. Cells were 
inoculated in a volume of 135 µl at a density of 5,000 cells per 
well. Cells were cultured for 4 days in the presence or absence 
of inhibitors. At the end of the treatment, 15 µl of 3-[4,5-dimeth-
ylthiazol-2yl]-2,5-diphenyltetrazolium bromide solution 
(5 mg/ml in PBS) was added, and the mixture was further 
incubated for 4 h. The resulting 3-[4,5-dimethylthiazol-2yl]-
2,5-diphenyltetrazolium bromide formazan was solubilized 
by addition of 100 µl of SDS solution (20% in 10 mm HCl), 
and the absorbance was measured after 24 h at 570 nm and a 
reference wavelength of 690 nm using a microplate reader (33). 
Colony-forming in soft agar assays were based on standard 
methods. Briefly, 2x104 cells were resuspended in 4 ml of 0.33% 
special Noble agar (Difco, Detroit, MI, USA) and plated (6-cm 
plate) in growth medium-containing 0.5% soft agar. Colonies 
were photographed 14 days after plating. FACS analysis was 
performed as described (34). Briefly, cells were harvested by 
trypsin-EDTA and washed; pellets were resuspended in 0.3 ml 
50% FCS in PBS, additioned with 0.9 ml 70% ethanol and left 
O/N in the dark at 4˚C before FACS analysis (Coulter Epics 
XL Flow Cytometer, Beckman Coulter, Brea, CA, USA).
Invasion and migration assays. Transwell membrane (Corning 
Costar Corporation, Corning, NY, USA) was used. Cancer 
cells were trypsinized, washed and kept suspended in the 
appropriate medium without FCS. Migration-inducing medium 
(with 10% FCS) was added to the lower wells of the chambers, 
while the upper wells were filled with serum-free medium with 
cells (20,000 cells per well) in the absence, as controls, or in the 
presence of the appropriate treatments. After 8 h, filters were 
removed and fixed with methanol and subsequently wiped on 
the cells on the upper side using the Q-tip. Filters were stained 
with 20% Giemsa solution. Evaluation of completed transmi-
gration was performed under a microscope, and random fields 
were scanned (four fields per filter) for the presence of cells at 
the lower membrane side only. Invasion assays were done in a 
similar manner as the migration assays described above, unless 
the inserts were pre-coated with Matrigel (BD Biosciences, 
Franklin Lakes, NJ, USA).
HIF-1α transcription factor assay. HIF-1α transcription factor 
activity was evaluated by HIF-1α Transcription Factor Assay 
(ab133104) from Abcam®. Transfection experiments were 
performed with siRNA for ERK1 and ERK2 or DNA-PKcs 
(Sancta Cruz Biotechnology) using Lipofectamine 2000 reagent 
(Invitrogen, San Giuliano Milanese, Milan, Italy), according 
to the manufacturer's instructions. Briefly, cells were plated 
at 40-50% confluence and transfected 24 h later with 100 nM 
siRNA, which we ascertained to be sufficient to detect maximum 
fluorescence using fluorescein-conjugated control siRNA.
Results
MEK/ERK inhibition blocks G0/G1 cell cycle phase transition 
and reverts transformed phenotype of glioblastoma cancer 
cells. Our experiments were started by verifying the role of 
MEKs/ERKs pathway through controlling cell cycle progres-
sion of growing GBM cancer cells in hypoxic conditions. For 
this purpose, T98G, U87MG, U138MG and U251MG GBM 
cell lines maintained under hypoxic conditions were treated 
with either U0126 (5, 10 or 20 µM) or vehicle and counted 
4 after days. MEKs/ERKs inhibition by U0126 arrested T98G, 
U87MG, U138MG in a concentration dependent manner while 
barely affecting the U251MG cells growth (Fig. 1A). FACS 
analysis showed that U0126 (10 µM) induced accumulation of 
T98G, U87MG, U138MG tumor cells in the G1 phase of cell 
cycle with weak effects on U251MG cells (Fig. 1B). Analysis 
of phospho/active-ERKs status and markers of G1 arrest was 
performed (Fig. 2A). As shown in Fig. 2, U0126 induced a 
rapid (12 h), highly persistent (24 h) ERK de-phosphoryla-
tion/inactivation in T98G, U87MG, U138MG cells while a 
much weaker phospho/active-ERK inhibition was observed 
in U251MG cells. ERK inhibition was concomitant to c-Myc 
and cyclin D1 downregulation while N-Myc levels where not 
modified with the exception of U251 line which expresses 
N-Myc at higher levels than the other cell lines. We tested 
the effects of MEK/ERK inhibition assessing the ability of 
GBM cells to grow, migrate and/or invade in an anchorage-
independent manner under hypoxic conditions. As show in 
Fig. 2, U0126 (10 µM) drastically reduced the ability of T98G, 
U87MG and U138MG to grow in suspension (Fig. 2B) and 
form colonies in soft agar (Fig. 2C), while these effects were 
less evident in U251MG cancer cells. Finally, U0126 (10 µM) 
significantly inhibited T98G, U87MG and U138MG invasion 
and migration at both 3 and 24 h post-treatment time points 
(Fig. 2D and E). Therefore, we concluded that MEK/ERK 
inhibition by U0126 induces growth arrest, which blocks the 
molecular mechanism responsible for G1 progression and 
reduces the tumorigenic and metastatic potential of GBM 
tumor cell growth under hypoxic conditions.
The hypoxia-induced increase of radioresistance and HIF-1α 
activity are counteracted by U0126-mediated MEK/ERK inhi-
bition. It has been shown that cancer cells exhibit different 
response to radiation therapy under hypoxia and normoxia. 
Since GBM usually acquires the ability to progress in 
hypoxic conditions, we tested whether U0126 affected radio-
sensitization ability under these two conditions. Tumor cells 
were cultured in the presence or absence of U0126 (10 µM) in 
normoxic or hypoxic conditions for 12 h before the delivery 
of increasing doses of ionizing radiation (0-6 Gy) (Fig. 3. left 
panels). After radiation treatment U0126 was removed and a 
colony assay was then performed. All cell lines were basi-
cally radioresistant under normoxic conditions (Fig. 3, left 
panels, normoxia+RT), while the hypoxic conditions highly 
increased (Fig. 3, left panels, hypoxia+RT) the intrinsic 
levels of radioresistance. U0126 increased the radiosensi-
tivity of T98G, U87MG and U138MG with effects evident 
both in normoxic and hypoxic conditions (Fig. 3, left panels, 
normoxia+U0126+RT, hypoxia+U0126+RT). No statistically 
significant differences were observed in the U251MG cell 
line (Fig. 3, left panels). We analyzed the HIF-1α activity 
present in the GBM cells after RT treatment (Fig. 3, right 
panels). HIF-1α basal activity increased under hypoxic 
condition in T98G, U87MG and U138MG while it was drasti-
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cally reduced upon MEK/ERK inhibition combined treatment 
(Fig. 3, right panels) which, by contrast, had no effect on 
HIF-1α activity status of U251MG cancer cells (Fig. 3, right 
panels). Noteworthy, RT treatment alone increased the HIF-1α 
basal activity both in normoxic and hypoxic conditions (Fig. 3, 
right panels).
MEK/ERK pathway is an upstream regulator of HIF-1α protein 
expression in GBM cancer cells. Since radiation increased 
HIF-1α activity in hypoxic conditions and MEK/ERK inhi-
bition combined with radiation affected HIF-1α activity, we 
investigated whether MEK/ERK pathways regulate HIF-1α 
protein expression in hypoxic conditions. GBM cell lines were 
cultured with or without U0126 (10 µM) in hypoxic condi-
tions for 12, 24 or 36 h; analysis of HIF-1α protein expression 
levels was performed (Fig. 4, right panels). MEK/ERK inhi-
bition by U0126 dramatically and persistently (12 to 36 h) 
reduced HIF-1α protein expression levels. In T98G as well 
as in U87MG and in U138MG cell lines the protein expres-
sion was completely abrogated (Fig. 4, left panels). U0126 
did not affect HIF-1α protein expression levels in U251MG 
GBM cancer cells. MEK/ERK pathway functioning upstream 
of HIF-1α in GBM, as suggested by U0126 experiments, was 
further demonstrated by RNA interference experiment with 
ERK1/ERK2- and scramble-siRNA in transient transfec-
tion. Three days after ERK1/ERK2 siRNA transfection, we 
Figure 1. Effects of MEK/ERK inhibition in GBM cell lines. (A) Growth curve of cultured T98G, U87MG, U138MG and U251MG GBM cell lines under 
hypoxia condition, in the presence (black bar) and absence (white bar) of 5, 10 or 20 µmol/l U0126 for 4 days. (B) FACS analysis of untreated and 6 or 12 h 
U0126 10 µmol/l U0126-treated T98G, U87MG, U138MG and U251MG GBM cell lines under hypoxia condition. Mean ± SE of triplicates of a representa-
tive experiment (*p<0.05 vs. untreated cells).
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observed a downregulation of total ERKs and a drastic reduc-
tion of HIF-1α in T98G, U87MG, U138MG and U251MG 
transfected cells (Fig. 4, right panels).
MEK/ERK inhibition by U0126 radiosensitizes GBM cancer 
cell lines by affecting the DNA repair molecular mechanism. 
We next investigated the molecular mechanism responsible 
Figure 2. MEK/ERK inhibition by U0126 affects G1 cell cycle phase marker proteins and  oncogenic potential of GBM cell lines. (A) Cell lysates from T98G, 
U87MG, U138MG and U251MG GBM cell lines untreated (-) or treated (+) with 10 µmol/l U0126 for indicated times were analysed by immunoblot analysis with 
specific antibodies for indicated proteins. α-tubulin expression shows the loading of samples. (B) Growth curve in Poly-HeMa coated plates of T98G, U87MG, 
U138MG and U251MG GBM cell lines untreated (white bar) or treated (black bar) with 10 µmol/l U0126. Cells were counted after 6 days. (C) T98G, U87MG, 
U138MG and U251MG GBM cell lines untreated (white bar) or treated (black bar) with 10 µmol/l U0126 were tested for growth in soft agar. Colonies were 
photographed after 14 days. (D) Transwell migration or (E) invasion assays of T98G, U87MG, U138MG and U251MG GBM cell lines untreated (white bar) or 
treated (black bar) with 10 µmol/l U0126 for 6 or 24 h. Cells number/field were counted. Similar results were obtained in three experiments. The data shown are 
the mean ± SEM of triplicates of a representative experiment (*p<0.05 vs. untreated cells).
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Figure 3. Effects of U0126 on GBM cancer cell line survival and on HIF-1α activation status after irradiation. (Left panels) T98G, U87MG, U138MG and 
U251MG GBM cell lines in the exponential phase of growth under hypoxic or normoxic conditions, were exposed to the indicated doses of γ-radiation. 
Clonogenic survival was determined by counting the number of colonies containing >50 cells after 2 weeks of growth. The surviving fraction is shown 
in a semi-logarithmic plot against radiation dose. Each point is the mean of triplicate flasks from two to three independent experiments; bars, SE. (Right 
panels) T98G, U87MG, U138MG and U251MG GBM cell lines in the exponential phase of growth under hypoxic conditions, were exposed to 400 cGy 
of γ-radiation in the presence or the absence of U0126. Analysis on HIF-1α activation status were performed after 1 h from γ-radiation. Similar results 
were obtained in three experiments. The data shown are the mean ± SEM of triplicates of a representative experiment (*p<0.05 vs. untreated cells under 
normoxia condition, §p<0.05 vs. untreated cells under hypoxia condition).
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of radiosensitization induced by MEK/ERK inhibition. 
DNA-PKcs and Ku proteins are upregulated in various tumors 
and are implicated in the radiation response. DNA-PKcs, 
Ku-80 and Ku-70 expression levels in response to U0126 were 
assessed by western blot analysis (Fig. 5A). The 24 h treat-
ment with U0126 alone, and in combination with radiation 
reduced DNA-PKcs, Ku-80 and Ku-70 protein expression 
levels concomitantly with HIF-1α downregulation in the 
T98G, U87MG and U138MG is shown in Fig. 5A. No change 
was observed in U0126-treated U251MG cells. RT treatment 
Figure 4. MEK/ERK inhibition counteracts the HIF-1α protein expression in GBM cancer cell lines. (Left panels) Cell lysates from T98G, U87MG, U138MG 
and U251MG GBM cell lines untreated (-) or treated (+) with 10 µmol/l U0126 for indicated times were analysed by immunoblotting with specific antibodies 
for indicated proteins. α-tubulin expression shows the loading of samples. Similar results were obtained in three different experiments. (Right panels) Cells 
were transfected with control (scramble) or ERK1/2 siRNAs and cultured for 3 days under hypoxia conditions. Immunoblot analyses of total lysates were 
performed using specific antibodies recognizing the indicated proteins. Similar results were obtained in two experiments.
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alone increased the level of phospho/active ERKs. RNA inter-
ference experiment with ERK1/ERK2- or scramble-siRNA in 
transient transfection confirmed that DNA-PKcs expression 
is under the control of ERKs (Fig. 5B). Three days after the 
transfection we observed a downregulation of total ERKs 
and a drastic reduction of DNA-PKcs in ERK1/ERK2 siRNA 
T98G, U87MG, U138MG and U251MG transfected cells 
(Fig. 5B).
MEK/ERK pathway regulates DNA-PKcs protein expres-
sion levels and controls HIF-1α protein accumulation and 
radioresistance of GBM cancer cells. Since MEK/ERK 
inhibition by U0126 or siRNA-mediated silencing induced 
HIF-1α and DNA-PKcs downregulation, we investigated 
if there was a functional correlation between DNA-PKcs 
and HIF-1α. T98G, U87MG, U138MG and U251MG were 
transiently transfected with either scramble control or 
DNA-PKcs-siRNA. Sixty hours after transfection the cells 
were exposed to hypoxic condition for 12 h. Finally, total 
lysates were processed for western blot analysis (Fig. 6A) and 
HIF-1α activity evaluation (Fig. 6B). DNA-PKcs silencing 
by siRNA reduced the HIF-1α protein expression levels 
(Fig. 6A) and activity (Fig. 6B) in T98G, U87MG, U138MG 
as well as in U251MG cell line. Since HIF-1α seemed to be 
the final regulator of the molecular mechanism governed by 
MEK/ERK pathway and responsible of GBM radioresistance, 
we tested whether the HIF-1α inhibition could radiosensitize 
GBM cells. For this experiment T98G, U87MG, U138MG and 
U251MG cancer cell lines were cultured in the presence or 
absence of FM19G11 (300 nM), a specific HIF-1α inhibitor, in 
hypoxic conditions for 12 h before the delivery of increasing 
doses of ionizing radiation (0-6 Gy). After radiation treatment, 
FM19G11 was removed and colony assay was performed 
(Fig. 6C). To test the inhibitory efficiency of FM19G11, 
HIF-1α activity was measured before the radiation delivery 
(Fig. 6D). HIF-1α inhibition by FM19G11 (Fig. 6D) reduced 
the radioresistance of T98G, U87MG, U138MG and U251MG 
cancer cells (Fig. 6C).
Discussion
Hypoxia is a negative prognostic and predictive factor, 
known to contribute to chemoresistance, radioresistance, 
angiogenesis, vasculogenesis, invasiveness, metastasis, 
resistance to cell death, altered metabolism and genomic 
instability. Given its central role in tumor progression and 
resistance to therapy, tumor hypoxia might well be consid-
ered the best validated target that has yet to be explored in 
oncology (35). Hypoxic stress has been linked to several 
phenotypic changes that are fundamental to GBM progres-
Figure 5. MEK/ERK inhibition abrogates the molecular mechanism responsible of DNA double strand break repair. (A) Cell lysates from T98G, U87MG, 
U138MG and U251MG GBM cell lines pre-treated (+) or not (-) with 10 µmol/l U0126 for 24 h under hypoxic conditions and then exposed to 400 cGy 
of γ-radiation were analysed by immunoblot analysis with specific antibodies for indicated proteins. α-tubulin expression shows the loading of samples. 
Similar results were obtained in three different experiments. (B) T98G, U87MG, U138MG and U251MG cells were transfected with control (scramble) 
or ERK1/2 siRNAs and cultured for 3 days under hypoxia conditions. Immunoblot analyses of total lysates were performed using specific antibodies 
recognizing the indicated proteins. Similar results were obtained in two experiments.
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sion and unresponsiveness of treatments (36). Even though 
Ras-MAPK pathway is important in radioresistance, where 
activated oncogenic Ras mediates resistance to ionizing radi-
ation (37), the role of its inhibition under hypoxic conditions 
and the downstream target in radiation response has not yet 
been investigated in GBM. In the present study, we addressed 
the issue on whether MEK/ERK inhibition, through targeting 
HIF-1α, prevents the transformed phenotype expression and 
radiation therapy resistance in several GBM cell lines grown 
under hypoxic conditions. Experimental conditions chosen, 
were based on data already present in the literature for which 
a near-maximal HIF-1α expression occurs at 12 h of hypoxia 
at an oxygen concentration of 0.1% O2, representing a level 
of hypoxia that is frequently observed in solid tumors and 
is radiobiologically relevant (38). Our data show that MEK/
ERK inhibition by U0126 reverts the transformed phenotype 
of T98G, U87MG and U138MG GBM cell lines by blocking 
the proliferation, migration and invasion under hypoxic condi-
tions. U251MG GBM cell line in which U0126 did not induce 
a persistent MEK/ERK inhibition, was unresponsive to the 
treatment. According to the literature (8-10), in the clonogenic 
assay, hypoxia increased the intrinsic levels of radioresistance 
in GBM cell lines that was counteracted by U0126 in T98G, 
U87MG and U138MG but not in U251MG cells. It has been 
shown that tumors deficient in the function or expression of 
HIF-1α present an enhanced response to radiotherapy in vivo 
and in vitro models (39-42). In this study we show that MEK/
ERK inhibition counteracted hypoxia-induced increment of 
HIF-1α basal activity and reduced HIF-1α protein expres-
sion levels in T98G, U87MG and U138MG GBM cell lines. 
Furthermore, we note that RT treatment, independently of 
oxygen concentration, increased MEK/ERK pathway activa-
tion and HIF-1α activity. We speculate that GBM cancer cells 
respond to radiation treatment by activating a pro-survival 
Figure 6. DNA-PKcs regulates HIF-1α protein accumulation and activity which inhibition affects GBM cancer cell lines survival. (A) T98G, U87MG, U138MG 
and U251MG cells were transfected with control (scramble) or DNA-PKcs siRNAs and cultured for 3 days under hypoxia conditions. Immunoblot analyses of 
total lysates were performed using specific antibodies recognizing the indicated proteins. Similar results were obtained in three experiments. (Right panels) 
(B) Analysis on HIF-1α activation status were performed. The data shown are the mean ± SEM of triplicates of a representative experiment. (C) T98G, U87MG, 
U138MG and U251MG GBM cell lines in the exponential phase of growth under hypoxic condition, were pre-treated for 24 h with FM19G11 (300 nM) and 
then exposed to the indicated doses of γ-radiation. Clonogenic survival was determined by counting the number of colonies containing >50 cells after 2 weeks 
of growth. The surviving fraction is shown in a semilogarithmic plot against radiation dose. Points, means from triplicate flasks from two to three independent 
experiments; bars, SE. (Right panels) T98G, U87MG, U138MG and U251MG GBM cell lines in the exponential phase of growth under hypoxic condition, were 
exposed to 400 cGy of γ-radiation. (D) Analysis on HIF-1α activation status were performed after 1 h from γ-radiation. Similar results were obtained in three 
experiments. The data shown are the mean ± SEM of triplicates of a representative experiment.
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molecular mechanism characterized by the MEK/ERK-HIF-1α 
interplay, which is interrupted by U0126 treatment. Thus, the 
molecular mechanism responsible of U0126 mediated radiosen-
sitiziation was further dissected. DNA-PKcs activity is known 
to be essential for the repair of DSBs in the cell, and substantial 
scientific evidence has shown that DNA-PKcs and Ku proteins 
strongly correlate with radiosensitivity/resistance in several 
types of cancer (43,44). Consistently, in T98G, U87MG and 
U138MG, but not in U251MG cell line, the synergistic effect of 
MEK/ERK inhibitor on irradiation results from the targeting 
of DNA-PKcs and Ku protein expression levels, most likely 
compromising DNA-repair mechanism. Even though functional 
interplay between HIF-1α and DNA-PK has been shown (26), 
there is no evidence on the molecular mechanism responsible 
for this relationship. Herein, for the first time we show that 
DNA-PKcs positively regulate HIF-1α protein expression levels 
and support its accumulation. Interestingly, the selective inhibi-
tion of DNA-PKcs by siRNA downregulates HIF-1α protein 
expression levels in all the GBM cell line tested including the 
U251MG cell line, which are unresponsive to U0126 treat-
ment. Thus, HIF-1α appears to be a downstream target of a 
complex molecular signal transduction pathway responsible 
of GBM radioresistance and its inhibition by FM19G11, 
HIF-1α inhibitor, drastically radiosensitizes GBM cells. Our 
data strongly suggest that HIF-1α is an attractive target for 
overcoming hypoxia-induced radioresistence. The selection 
of clinically promising HIF-1α targeting agents represents an 
essential step towards identifying new radiosensitive agents. In 
conclusion, we demonstrated that through signal transduction-
based chemotherapy it is possible to radiosensitize GBM 
cancer cells by interrupting the interplay between MEK/ERK 
and DNA-PKcs pathways and preventing HIF-1α-mediated 
hypoxic cell survival and DNA-PKcs-mediated cancer cells 
radiation escape. MEK/ERK or HIF-1α inhibitors combined 
with radiation are an efficient antitumor treatment for GBM 
cell lines suggesting a successful therapy to be tested in vivo 
and translated to clinic.
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